Zainel, I., Hammodi, S. (2023). Immunohistochemical Expression of P53 in Gastric Adenocarcinoma. , 22(2), 224-229. doi: 10.52573/ipmj.2023.180593
Iman Abbas Zainel; Salim Rasheed Hammodi. "Immunohistochemical Expression of P53 in Gastric Adenocarcinoma". , 22, 2, 2023, 224-229. doi: 10.52573/ipmj.2023.180593
Zainel, I., Hammodi, S. (2023). 'Immunohistochemical Expression of P53 in Gastric Adenocarcinoma', , 22(2), pp. 224-229. doi: 10.52573/ipmj.2023.180593
Zainel, I., Hammodi, S. Immunohistochemical Expression of P53 in Gastric Adenocarcinoma. , 2023; 22(2): 224-229. doi: 10.52573/ipmj.2023.180593

Immunohistochemical Expression of P53 in Gastric Adenocarcinoma

Iraqi Postgraduate Medical Journal
Volume 22, Issue 2, April 2023, Pages 224-229    PDF (523.7 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2023.180593
Authors
Iman Abbas Zainel; Salim Rasheed Hammodi
Department of Pathology, College of Medicine / University of Baghdad, Baghdad, Iraq
Abstract
ABSTRACT:
BACKGROUND:
Gastric carcinoma is the fifth most common cancer worldwide. P53 is tumor suppressor gene, located on chromosome 17p13.1, involved in cell senescence and differentiation. In gastric cancer, P53 expression had shown to be associated with bad prognosis.
AIMS OF THE STUDY:
To determine P53 immunohistochemical expression in gastric adenocarcinoma and correlate it with clinic-pathological variables.
MATERIALS AND METHODS:
Forty formalin fixed, paraffin embedded tissue blocks (24 endoscopic biopsies & 16 gastrectomy cases) included in this retrospective study, collected from archived materials from Baghdad hospitals & laboratories (from January 2019 to December 2020).
Two sections of 5μm thickness were done, one stained with H&E and the other for P53 using mouse monoclonal antibody (clone BP-53-12).
RESULTS:
Immunohistochemical expression of P53 was expressed in 32 cases (80%) (24 cases intestinal type adenocarcinoma & 8 cases diffuse type adenocarcinoma). Five had score +1, eleven had score +2 and sixteen had score +3. Twelve lymph nodes positively expressed p53, eleven of them (91.7 %) involved by metastatasis.
CONCLUSION:
P53 significantly expressed in intestinal type adenocarcinoma and directly related with tumor differentiation, depth of invasion and lymph node metastasis but not with tumor location.
 
 
Keywords
P53 expression; gastric adenocarcinoma
References
REFERENCES:

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68:394-424.
  2. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. The Lancet. 2016 ;388:2654-64.
  3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World journal of gastroenterology: WJG. 2006 ;12:354.
  4. Topi S, Santacroce L, Bottalico L, Ballini A, Inchingolo AD, Dipalma G, Charitos IA, Inchingolo F. Gastric cancer in history: A perspective interdisciplinary study. Cancers. 2020;12:264.
  5. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013;6:l1.
  6. Klimstra DS, Hruban RH, Pitman MB.Pancreas. In: Mills SE, ed. Histology for Pathologists. 3rd ed. Philadelphia: Lippincot Williams and Wilkins; 2007:723-60.
  7. Klimstra DS, Hruban RH, Pitman MB.Pancreas. In: Mills SE, ed. Histology for Pathologists. 3rd ed. Philadelphia: Lippincot Williams and Wilkins; 2007:723-60.
  8. Shi S, Hua J, Liang C, Meng Q, Liang D, Xu J, Ni Q, Yu X. Proposed modification of the 8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma. Annals of surgery. 2019 ;269:944-50.
  9. Hermiz RS, Hussain AG, Qasim JG. Immunohistochemical expression of p53 in gastric carcinoma (A Clinicopathological study). Iraqi J. Med. Sci. 2008;6:77-89.
  10. Rayan A. Kasim. P53 expression in gastric cancer in Ninavah province. Fac Med Bag 2014;53:190-93.
  11. Ando K, Oki E, Zhao Y, Ikawa-Yoshida A, Kitao H, Saeki H, Kimura Y, Ida S, Morita M, Kusumoto T, Maehara Y. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer. 2014;17:255-62.
  12. Grosser B, Kohlruss M, Slotta-Huspenina J, Jesinghaus M, Pfarr N, Steiger K, Novotny A, Gaida MM, Schmidt T, Hapfelmeier A, Ott K. Impact of tumor localization and molecular subtypes on the prognostic and predictive significance of p53 expression in gastric cancer. Cancers. 2020;12:1689.
  13. Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF, Takano Y, Zheng HC. Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas. Oncology Letters. 2013;6:1277-84.
  14. Ghaffarazadegan K, Zali M, Ahmadi Kh , et al. Correlation of nuclear p53 immunoreactive with histopathologic features in gastric cancer. Archive of Iranian Med 2004;7:279-83.
  15. Al-Badri BA, Ali GQ. P53 Expression in Gastric Dysplasia and carcinoma in Erbil city. Journal of the Faculty of Medicine Baghdad. 2011;53:190-93.
  16. Salih BA, Gucin Z, Bayyurt N. A study on the effect of Helicobacter pylori infection on p53 expression in gastric cancer and gastritis tissues. The Journal of Infection in Developing Countries. 2013;7:651-57.
  17. Flejou JF, Gratio V, Muzeau F, Hamelin R. p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Molecular Pathology. 1999;52:263.
Statistics
Article View: 305
PDF Download: 229


Journal Management System. Powered by iJournalPro.com